1999
Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters
Sterling T, Lyles C, Vlahov D, Astemborski J, Margolick J, Quinn T. Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters. The Journal Of Infectious Diseases 1999, 180: 666-672. PMID: 10438353, DOI: 10.1086/314967.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 RNA levelsHIV-1 seroconvertersSex differencesCopies/mLHIV-1 pathogenesisInjection drug usersCase-control studyTime of seroconversionCross-sectional studyCourse of infectionMale patientsRapid progressorsFemale patientsCopies/Drug usersMale controlsVirus levelsPatientsRNA levelsSeroconvertersWomenMenNonprogressorsSeroconversionProgressorsDirect Comparison of Time to AIDS and Infectious Disease Death Between HIV Seroconverter Injection Drug Users in Italy and the United States: Results From the ALIVE and ISS Studies
Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles C, Astemborski J. Direct Comparison of Time to AIDS and Infectious Disease Death Between HIV Seroconverter Injection Drug Users in Italy and the United States: Results From the ALIVE and ISS Studies. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 20: 275-282. PMID: 10077177, DOI: 10.1097/00042560-199903010-00010.Peer-Reviewed Original ResearchConceptsInjection drug usersDate of seroconversionYear of seroconversionMedian timeRelative hazardGroups of IDUsDrug usersInfectious diseasesCohort of IDUsFirst positive HIV testClinic-based cohortSimilar median timeHIV disease progressionProspective cohort studyPositive HIV testInjection drug useCommunity-based cohortHIV-positive individualsInfectious disease deathsTime of seroconversionDrug use characteristicsTerms of ageProportion of womenALIVE studyCohort studyPersistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection
Villano S, Vlahov D, Nelson K, Cohn S, Thomas D. Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection. Hepatology 1999, 29: 908-914. PMID: 10051497, DOI: 10.1002/hep.510290311.Peer-Reviewed Original ResearchConceptsRecombinant immunoblot assayHCV RNAAcute infectionViral clearanceAcute hepatitis C virus (HCV) infectionAcute hepatitis C infectionHepatitis C virus infectionPersistence of viremiaAcute HCV infectionAcute hepatitis CC virus infectionHepatitis C infectionTime of seroconversionPeak viral titersHealth care providersSingle laboratory testIllicit drug useHCV seroconversionC infectionHCV infectionHepatitis CPersistent viremiaClinical featuresHCV subtypesPolymerase chain reaction
1996
Alcohol Use and T‐Lymphocyte Subsets among Injection Drug Users with HIV‐1 Infection: A Prospective Analysis
Crum R, Galai N, Cohn S, Celentano D, Vlahov D. Alcohol Use and T‐Lymphocyte Subsets among Injection Drug Users with HIV‐1 Infection: A Prospective Analysis. Alcohol Clinical And Experimental Research 1996, 20: 364-371. PMID: 8730231, DOI: 10.1111/j.1530-0277.1996.tb01654.x.Peer-Reviewed Original ResearchConceptsInjection drug usersCohort of IDUsT lymphocyte subsetsDrinks/weekHIV seroconversionAlcohol useYears postseroconversionDrug usersAlcohol categoriesHIV-positive injection drug usersCD8 absolute countsHIV-1 seroconvertersProgression of immunodeficiencyLevels of CD4Intravenous drug useT lymphocyte subpopulationsFirst prospective studyHIV-1 infectionTime of seroconversionSignificant differencesEarly intervention programsHIV infectionHIV progressionOutpatient clinicProspective study
1992
Changes in T-Lymphocyte Subsets in Intravenous Drug Users With HIV-1 Infection
Margolick J, Muñoz A, Vlahov D, Solomon L, Astemborski J, Cohn S, Nelson K. Changes in T-Lymphocyte Subsets in Intravenous Drug Users With HIV-1 Infection. JAMA 1992, 267: 1631-1636. PMID: 1347321, DOI: 10.1001/jama.1992.03480120069035.Peer-Reviewed Original ResearchConceptsSeropositive intravenous drug usersIntravenous drug usersHIV-1 infectionHIV-1-seropositive intravenous drug usersDrug usersCell countSeronegative intravenous drug usersHuman immunodeficiency virus type 1Complete blood cell countImmunodeficiency virus type 1Absolute numberCD4 cell countCD4 lymphocyte countPercentage of CD4T lymphocyte subsetsCD8 T cellsT cell subsetsCommunity-based clinicsBlood cell countTime of seroconversionVirus type 1Multivariate regression analysisUse of drugsCD4 lymphocytesCD8 lymphocytes